Gastrointestinal Stromal Tumor Treatment in India
Get Gastrointestinal Stromal Tumor Treatment at internationally accredited (JCI/NABH) Indian hospitals at a fraction of Western costs, with end-to-end international patient support — visa, travel, stay, and follow-up care.
Gastrointestinal Stromal Tumor Treatment in UAE
Gastrointestinal Stromal Tumor Treatment at leading UAE hospitals in Dubai and Abu Dhabi — world-class care closer to home, visa-free entry for many nationalities, international specialists, and modern facilities.
Overview
Gastrointestinal Stromal Tumor (GIST) treatment encompasses a multidisciplinary approach combining targeted molecular therapy (primarily imatinib and sunitinib), precision oncological surgery, and advanced pathological staging, achieving long-term disease control in over 80% of localized GIST cases and meaningful remission in metastatic disease. International patients choose India and the UAE for GIST care due to access to high-volume sarcoma centers staffed by oncologists trained at leading global institutions, with treatment costs a fraction of those in Western countries. GAF Healthcare connects patients to JCI- and NABH-accredited hospitals in India and JCI- and DHA-accredited centers in Dubai and Abu Dhabi, providing end-to-end coordination from diagnosis review to post-treatment surveillance.
Hospital Stay: 7–14 days (varies by surgical extent and medical management phase) • Total Stay in Country (Fit-to-Fly): 3–6 weeks (longer for open resections or complex cytoreductive procedures; targeted therapy patients may travel earlier with oncologist clearance) • Success Rate: 85–90% for localized GIST (R0 resection); 70–80% progression-free survival at 1 year for metastatic disease on first-line imatinib
What Is It?
Gastrointestinal Stromal Tumors (GISTs) are the most common mesenchymal neoplasms of the gastrointestinal tract, arising predominantly from the interstitial cells of Cajal or their precursors. They occur most frequently in the stomach (60%) and small intestine (25%), with the remainder distributed across the colon, rectum, esophagus, and mesentery. Unlike epithelial GI cancers, GISTs are defined by activating mutations in the KIT proto-oncogene (approximately 75–80% of cases), PDGFRA (10–15%), or, in a minority of cases, by NF1 mutations, SDH deficiency, or BRAF alterations. These driver mutations make GIST uniquely susceptible to tyrosine kinase inhibitor (TKI) therapy, fundamentally altering the treatment landscape since 2001.
Physiologically, GISTs can grow to significant size before causing symptoms, often presenting with vague abdominal discomfort, early satiety, gastrointestinal bleeding, or a palpable mass. Larger or strategically located tumors may cause obstruction, perforation, or hemorrhage. Risk stratification — using the modified NIH consensus criteria or the Armed Forces Institute of Pathology (AFIP) system — incorporates tumor size, mitotic index (per 50 high-power fields), and primary site to classify tumors as very low, low, intermediate, or high risk. This stratification directly governs adjuvant TKI decisions and surveillance intensity.
The current standard of care for resectable localized GIST is complete surgical resection (R0) with negative margins, performed without lymphadenectomy (as lymphatic spread is rare) but with careful attention to pseudocapsule integrity to prevent intraperitoneal dissemination. Adjuvant imatinib (400 mg/day) is recommended for three years in KIT-mutated intermediate- and high-risk tumors, based on ACOSOG Z9001 and SSGXVIII trial data demonstrating improved recurrence-free and overall survival. For metastatic or unresectable disease, imatinib remains first-line therapy; sunitinib is standard second-line; regorafenib is third-line. Emerging agents — ripretinib (fourth-line) and avapritinib (for PDGFRA D842V-mutated GIST) — have expanded the treatment arsenal significantly in recent years.
Candidates
• CONFIRMED GIST DIAGNOSIS: Patients with histologically confirmed GIST via endoscopic ultrasound-guided fine-needle biopsy (EUS-FNA), CT/MRI-guided core needle biopsy, or surgical specimen with immunohistochemistry positive for CD117 (KIT), DOG1, and/or CD34
• MOLECULAR PROFILING REQUIRED: KIT exon 9, 11, 13, 17 and PDGFRA exon 12, 14, 18 mutational analysis is mandatory before initiating TKI therapy; SDH subunit testing for wild-type GIST
• SURGICAL CANDIDATES: Patients with localized, resectable GIST (ECOG performance status 0–2) without major comorbidities precluding general anesthesia; tumor size and location must be assessed for feasibility of R0 resection
• NEOADJUVANT IMATINIB CANDIDATES: Patients with large (>5 cm), borderline resectable, or anatomically complex tumors (gastroesophageal junction, duodenum, rectum) where preoperative TKI downsizing improves surgical outcomes or enables organ-sparing resection
• METASTATIC/UNRESECTABLE PATIENTS: Patients with hepatic, peritoneal, or distant metastases who are candidates for systemic TKI therapy; may also be candidates for cytoreductive surgery or radiofrequency ablation (RFA) of limited hepatic disease after response to imatinib
• REQUIRED PRE-TREATMENT DIAGNOSTICS: Contrast-enhanced CT of chest, abdomen, and pelvis; FDG-PET/CT (especially for treatment response assessment); MRI abdomen (preferred for rectal/pelvic GIST); EUS for intramural tumors; complete blood count, liver and renal function tests, echocardiogram (ECHO) prior to sunitinib initiation; bone marrow biopsy if SDH-deficient GIST suspected
• CONTRAINDICATIONS TO SURGERY: Diffuse peritoneal carcinomatosis without prior TKI response, significant cardiopulmonary compromise (ejection fraction <40% or FEV1 <50% predicted), uncontrolled coagulopathy, or patient refusal of resection
• CONTRAINDICATIONS TO IMATINIB: Severe hepatic impairment (Child-Pugh C), known hypersensitivity to imatinib; PDGFRA D842V mutation confers primary imatinib resistance — avapritinib is the preferred agent for this subtype
• PEDIATRIC AND SDH-DEFICIENT GIST: Requires specialized multidisciplinary evaluation; these tumors behave differently, are often TKI-resistant, and may require mTOR inhibitor-based or watch-and-wait strategies
Procedure
SURGICAL APPROACHES:
Open Resection: Traditional approach for large (>10 cm), adherent, or anatomically complex GISTs. Involves en-bloc resection of the tumor with a 1–2 cm margin of normal tissue. No formal lymph node dissection is required. Gastric wedge resection, segmental small bowel resection, or partial colectomy are the most common procedures depending on the primary site. Careful handling of the pseudocapsule is paramount — rupture during resection converts R0 to R1/R2 status and significantly worsens prognosis.
Laparoscopic / Minimally Invasive Resection: Appropriate for gastric GISTs ≤5 cm and select small intestinal lesions in experienced centers. Techniques include laparoscopic wedge resection using endoscopic stapling devices, laparoscopic-endoscopic cooperative surgery (LECS), and intragastric laparoscopic resection for intraluminal tumors near the cardia or pylorus. Benefits include reduced blood loss, shorter hospital stay (5–7 days vs. 10–14 days for open), and faster return to oral tyrosine kinase therapy.
Robotic-Assisted Surgery: Utilized for GISTs in anatomically challenging locations — gastroesophageal junction, posterior gastric wall, duodenum, and rectum. The da Vinci Surgical System provides enhanced three-dimensional visualization and 7-degree-of-freedom articulation, facilitating precise dissection in confined spaces while minimizing tumor manipulation risk. Available at premium centers in India (Apollo, Fortis, Tata Memorial) and UAE (Cleveland Clinic Abu Dhabi, Mediclinic City Hospital Dubai).
Endoscopic Resection: Endoscopic submucosal dissection (ESD) or endoscopic full-thickness resection (EFTR) may be considered for very small (<2 cm), low-risk intramural gastric GISTs, particularly in patients unfit for surgery. Requires highly specialized endoscopic expertise and careful oncological counseling.
TARGETED SYSTEMIC THERAPY:
Imatinib (Gleevec/Glivec) — First-Line: 400 mg/day orally for KIT exon 11-mutated GIST (standard); 800 mg/day for KIT exon 9-mutated metastatic GIST (higher dose improves progression-free survival). Used in the neoadjuvant setting (typically 6–12 months) for downsizing borderline resectable tumors, and as adjuvant therapy for 3 years post-resection in high-risk KIT-mutated GIST.
Sunitinib (Sutent) — Second-Line: 50 mg/day on a 4-weeks-on/2-weeks-off schedule, or 37.5 mg continuous dosing. Standard for imatinib-resistant or intolerant patients. Monitoring for hypertension, hypothyroidism, hand-foot syndrome, and cardiotoxicity (serial ECHO required).
Regorafenib (Stivarga) — Third-Line: 160 mg/day for 3 weeks on/1 week off. Approved based on GRID trial data. Hepatotoxicity monitoring is essential.
Ripretinib (Qinlock) — Fourth-Line: 150 mg/day continuously. A switch-control kinase inhibitor with broad KIT/PDGFRA mutation coverage; approved based on INVICTUS trial.
Avapritinib (Ayvakit) — For PDGFRA D842V-Mutated GIST: 300 mg/day on an empty stomach. First and only agent with demonstrated efficacy in this classically imatinib-resistant subtype (NAVIGATOR trial: ORR ~90%).
INTERVENTIONAL ONCOLOGY FOR METASTATIC DISEASE:
Radiofrequency Ablation (RFA) and Microwave Ablation (MWA): For oligometastatic hepatic GIST with limited lesion burden (<3–5 lesions, each <3 cm) responding to imatinib. Can be combined with surgical resection in a hybrid approach.
Transarterial Chemoembolization (TACE) / Selective Internal Radiation Therapy (SIRT/Y-90): Reserved for hepatic-dominant metastatic GIST with TKI-stable or slowly progressive disease. SIRT with yttrium-90 microspheres is emerging as a promising option in specialized centers.
Imatinib Dose Escalation and Treatment Holidays: Structured TKI holidays under close surveillance (FDG-PET/CT at 8–12 week intervals) may be considered in select stable metastatic patients to manage cumulative toxicity.
Cost of Gastrointestinal Stromal Tumor Treatment: India vs. UAE
The cost of GIST treatment varies substantially depending on the treatment modality (surgical resection vs. targeted therapy alone vs. combined approach), the complexity of the procedure, tumor location, and the duration of systemic therapy required. India consistently offers world-class oncological care at 50–65% lower cost than the UAE, while both destinations offer significant savings compared to the United States (where GIST surgery alone may cost $60,000–$120,000+). The estimates below reflect a complete treatment episode including hospitalization, surgery or initial TKI course, pathology, and standard post-operative care; long-term TKI drug costs are ongoing and should be budgeted separately (generic imatinib is widely available in India at significantly reduced cost).
| Destination | Estimated Cost (USD) | Key Advantage |
|---|---|---|
| India | $4,500 – $12,000 | ~59% less than the UAE |
| UAE (Dubai/Abu Dhabi) | $12,000 – $28,000 | Premium care, JCI/DHA accredited |
Estimates typically include surgery, hospital stay, and standard medications. Contact us for a personalised quote.
Recovery & Aftercare
PHASE 1 — PRE-ARRIVAL (2–4 weeks before travel):
• GAF Healthcare case managers review all existing pathology reports, CT/MRI imaging, and molecular profiling results with the receiving oncology team
• Multidisciplinary tumor board (MDT) review including surgical oncology, medical oncology, radiology, and pathology is convened virtually before patient arrival
• E-Medical visa application initiated for India (typically approved within 3–5 business days); UAE visit visa or medical visa arranged as applicable
• Travel itinerary, airport pickup, and accommodation for patient and attendant confirmed
PHASE 2 — ARRIVAL AND WORKUP (Days 1–5):
• Day 1: Airport transfer to hospital-affiliated accommodation; orientation meeting with dedicated GAF Healthcare patient coordinator
• Days 2–3: Repeat or confirmatory imaging (contrast-enhanced CT or MRI abdomen/pelvis; FDG-PET/CT if not done recently); review of international pathology slides by local sarcoma pathologist
• Day 4: Anesthesiology pre-operative assessment, cardiopulmonary fitness evaluation (ECHO if sunitinib planned; pulmonary function tests if indicated); nutritional assessment
• Day 5: Final MDT decision on treatment strategy; patient and family counseling session; informed consent
PHASE 3 — TREATMENT (Days 6–20, variable by approach):
• SURGICAL PATIENTS (Laparoscopic): Procedure performed on Day 6; operative time 2–4 hours; ICU monitoring for 12–24 hours post-operatively
• SURGICAL PATIENTS (Open/Robotic): Procedure on Day 6–7 (after bowel prep if needed); ICU stay 1–2 days; total hospital stay 10–14 days
• Nasogastric tube removed by Day 1–2 post-op; liquid diet initiated Day 2–3; soft diet by Day 4–5
• Drain management and wound assessment performed daily; mobilization (ambulation) begins Day 1 post-op
• NEOADJUVANT/MEDICAL MANAGEMENT PATIENTS: Imatinib initiated after baseline labs; response assessed by FDG-PET/CT at 4–8 weeks; surgical planning follows upon adequate tumor response
PHASE 4 — POST-OPERATIVE RECOVERY AND DISCHARGE (Days 14–21):
• Pathology report available within 5–7 days of surgery: R0 status confirmed, mitotic index reported, final risk stratification determined
• Adjuvant imatinib prescription, dosing schedule, and toxicity monitoring protocol issued
• Wound check and suture/staple removal at Day 10–14
• Discharge criteria: tolerating oral diet, pain controlled on oral analgesics, no fever or signs of anastomotic leak
• Discharge summary, surgical operative report, histopathology, and molecular data compiled for home oncologist
PHASE 5 — FIT-TO-FLY AND LONG-HAUL CLEARANCE (Weeks 3–6):
• Laparoscopic resection patients: Fit for short-haul flight (≤4 hours) at Week 2–3; long-haul (>6 hours) at Week 3–4 with DVT prophylaxis (compression stockings, low-molecular-weight heparin if indicated)
• Open/robotic resection patients: Fit to fly long-haul at Week 4–6; wound integrity and absence of ileus must be confirmed
• Medical management (TKI-only) patients: May travel within 1–2 weeks if hemodynamically stable with no significant adverse effects
• Follow-up surveillance protocol: CT chest/abdomen/pelvis every 3–6 months for 3–5 years; annual FDG-PET/CT in high-risk cases; imatinib compliance monitoring via home oncologist
Risks & Considerations
GIST treatment carries procedure-specific and therapy-specific risks that must be transparently communicated to all international patients. Surgical risks include intraoperative tumor rupture (which upstages disease and worsens prognosis — incidence approximately 5–10% in experienced centers), anastomotic leak (2–5% for bowel resections), hemorrhage requiring transfusion, wound infection, and ileus. Laparoscopic and robotic approaches reduce wound complications but carry a risk of port-site recurrence if tumor integrity is compromised. Open surgery carries higher rates of adhesion-related complications and longer recovery. Imatinib side effects — occurring in the majority of patients — include periorbital and peripheral edema, nausea, fatigue, muscle cramps, diarrhea, and rash; severe hepatotoxicity (ALT >5x ULN) occurs in approximately 3–5% of patients. Sunitinib carries additional cardiovascular risk: hypertension occurs in 30–40% of patients, left ventricular dysfunction in 8–15% (necessitating baseline and serial echocardiography), and hypothyroidism in up to 50% on long-term therapy. Avapritinib carries a unique CNS risk of intracranial hemorrhage and cognitive effects (memory impairment, confusional episodes) in approximately 3–4% of patients, requiring dose interruption or reduction. Disease-specific risks include peritoneal dissemination from tumor rupture (which significantly worsens 5-year survival from approximately 70% to 30–40%), secondary KIT/PDGFRA resistance mutations driving TKI failure, and rare transformation to a more aggressive histological phenotype. All patients should be counseled that surveillance non-compliance substantially increases the risk of late recurrence detection. International patients must establish a clear continuity-of-care plan with their home oncologist before departure, particularly for ongoing TKI management.
Top Hospitals for Gastrointestinal Stromal Tumor Treatment
Top Doctors for Gastrointestinal Stromal Tumor Treatment
Internationally trained specialists in Gastroenterology. Review their profiles, compare experience, and connect directly through GAF Healthcare.
Dr. Rashmi Pyasi
MBBS, MS (General Surgery), FIAGES, FAIS, FALS
Bariatric & Gastrointestinal Surgeon
Fortis Memorial Research Institute, Gurgaon, India
28+ Yearsof experience
Dr. Rashmi Pyasi is an accomplished bariatric and gastrointestinal surgeon with over 28 years of clinical experience. She serves as Director of GI, Minimal Access & Bariatric Surgery at Fortis Memorial Research Institute in Gurgaon, one of India's leading multi-specialty hospitals. Dr. Pyasi holds a degree in MBBS from Gandhi Medical College, Bhopal, along with an MS in General Surgery and fellowships from the Indian Association of Gastrointestinal Endo… Read more
Dr. Abhishek Aggarwal
MBBS, MS (General Surgery), MCh (Gastrointestinal Surgery)
Gastrointestinal Oncosurgeon
BLK-Max Super Speciality Hospital, New Delhi, India
15+ Yearsof experience
Dr. Abhishek Aggarwal is an Associate Director of Gastrointestinal Oncosurgery at BLK-Max Super Speciality Hospital in New Delhi, bringing over 15 years of clinical and surgical expertise to the treatment of complex gastrointestinal and hepatopancreatobiliary malignancies. He trained at the All India Institute of Medical Sciences (AIIMS), Delhi, where he earned his MCh in Gastrointestinal Surgery, establishing a foundation of academic rigour and technical… Read more
Dr. Gopi Srikanth
MBBS, MD Internal Medicine, DM Gastroenterology and Hepatology, Fellowship in Pancreatology, Fellowship in Endoscopic Ultrasound
Gastroenterologist
Yashoda Hospitals, Hyderabad, India
10+ Yearsof experience
Dr. Gopi Srikanth is a Consultant Gastroenterologist and Hepatobiliary specialist at Yashoda Hospitals in Hyderabad, bringing over 10 years of clinical expertise in digestive and liver disease management. He holds a DM in Gastroenterology and Hepatology from AIIMS New Delhi and completed advanced fellowships in Pancreatology and Endoscopic Ultrasound from prestigious institutions including the World Endoscopy Organisation, which distinguish him as a… Read more
Dr. Guruprasad Shetty
MBBS, MS (General Surgery), DNB (General Surgery), FMAS, FIAGES, Fellowship in Surgical Gastroenterology and Minimally Invasive Surgery
Surgical Gastroenterologist & Hepatobiliary Surgeon
Apollo Hospitals, Mumbai, India
15+ Yearsof experience
Dr. Guruprasad Shetty is a Senior Consultant in Surgical Gastroenterology, Hepatopancreaticobiliary, and Transplant Surgery at Apollo Hospitals in Mumbai, bringing over 15 years of specialized surgical expertise. He holds exceptional credentials including MBBS, MS in General Surgery, DNB, FMAS (Fellowship in Minimal Access Surgery), and FIAGES, alongside a specialized fellowship in Surgical Gastroenterology and Minimally Invasive Surgery. His… Read more
Dr. Hitesh Panchal
MBBS, MD in Internal Medicine, DrNB in Gastroenterology
Gastroenterologist
Medanta - The Medicity, Gurgaon, India
9+ Yearsof experience
Dr. Hitesh Panchal is an Associate Consultant in Gastroenterology & Hepatobiliary Medicine at Medanta – The Medicity in Gurgaon, bringing 9+ years of clinical experience to the care of complex digestive and liver disorders. He completed his medical training at the esteemed B.J. Medical College, Ahmedabad, earning his MBBS in 2017 and MD in Internal Medicine in 2020, before pursuing his DrNB in Gastroenterology at Medanta, one of India's leading… Read more
Frequently Asked Questions — Gastrointestinal Stromal Tumor Treatment
The cost of GIST treatment in India typically ranges from USD 4,500 to USD 12,000 for a complete treatment episode including surgery (laparoscopic or open resection), hospitalization, pathology with molecular profiling, and initial post-operative care. In the UAE (Dubai or Abu Dhabi), the equivalent treatment costs between USD 12,000 and USD 28,000, reflecting the higher operational costs of UAE healthcare facilities while still representing significant savings compared to Western countries where GIST surgery alone can exceed USD 60,000–120,000. Both destinations offer JCI-accredited hospitals with access to the full spectrum of targeted therapies including imatinib, sunitinib, regorafenib, ripretinib, and avapritinib. It is important to note that ongoing tyrosine kinase inhibitor (TKI) therapy — typically 3 years of adjuvant imatinib for high-risk resected GIST — represents an additional ongoing medication cost; generic imatinib is substantially less expensive in India than in the UAE or Western markets. GAF Healthcare provides a detailed, itemized cost estimate after review of the patient's specific case, tumor characteristics, and planned treatment modality.
The duration of stay required before safe long-haul air travel depends directly on the treatment modality received. Patients who undergo laparoscopic or robotic-assisted GIST resection generally require a minimum of 3–4 weeks in-country: approximately 5–8 days of hospitalization, followed by 2–3 weeks of outpatient recovery for wound healing, return of bowel function, and post-operative pathology review. Clearance for long-haul flights (over 6 hours) is typically given at the 3–4 week mark, provided there are no complications. Patients who undergo open (laparotomy) resection — typically for larger or more complex GISTs — require 4–6 weeks before long-haul travel is considered safe, as the risk of ileus, wound dehiscence, and deep vein thrombosis (DVT) is higher in the immediate post-operative period. For all surgical patients, compression stockings and, in some cases, low-molecular-weight heparin prophylaxis are prescribed for the flight. Patients being treated with systemic targeted therapy alone (neoadjuvant imatinib for downsizing, or first-line TKI for metastatic GIST) can typically travel within 1–2 weeks of treatment initiation, once baseline tolerability of the drug is confirmed and any initial side effects (edema, nausea, fatigue) are managed. GAF Healthcare's medical team will issue a formal fit-to-fly clearance letter, which patients should carry alongside their discharge summary.
The success rate of GIST treatment is highly favorable compared to most other gastrointestinal malignancies, particularly when the tumor is diagnosed at a localized stage and treated with complete surgical resection (R0) followed by appropriate adjuvant targeted therapy. For localized, completely resected GIST in patients who receive 3 years of adjuvant imatinib (KIT-mutated, intermediate- to high-risk tumors), the 5-year recurrence-free survival rate is approximately 65–70%, with 5-year overall survival exceeding 85–90% in high-volume sarcoma centers. For very low- and low-risk resected GISTs (small tumor, low mitotic index), surgery alone achieves 5-year survival rates approaching 95%. For metastatic or unresectable GIST treated with first-line imatinib, objective response rates (complete plus partial response) are approximately 50–60%, with disease stabilization in an additional 25–30% of patients; median progression-free survival on imatinib is approximately 18–24 months. The introduction of subsequent-line TKIs has extended median overall survival in metastatic GIST to over 5 years in contemporary series. Key factors influencing outcomes include the primary mutation type (KIT exon 11-mutated tumors respond best to imatinib; KIT exon 9-mutated tumors require higher-dose imatinib; PDGFRA D842V-mutated tumors are imatinib-resistant but highly responsive to avapritinib), tumor size, mitotic rate, primary site, completeness of surgical resection (R0 vs. R1/R2), and avoidance of intraoperative tumor rupture. GAF Healthcare connects patients with high-volume sarcoma units that have treated over 500 GIST cases, which is associated with significantly better surgical and oncological outcomes compared to general surgery settings.
Why Plan Your Treatment Through Gaf Healthcare?
GAF Healthcare provides comprehensive end-to-end logistical support specifically designed for international oncology patients traveling to India or the UAE for GIST treatment.
INDIA LOGISTICS: E-Medical Visa: GAF Healthcare's visa team prepares and submits the Indian e-Medical Visa application on behalf of the patient and up to two attendants. The e-Medical Visa is typically approved within 3–5 business days and permits multiple entries for a 60-day period. Extensions can be arranged through the Foreigners Regional Registration Office (FRRO) for patients requiring prolonged TKI initiation and monitoring stays. A formal invitation letter from the treating hospital (arranged by GAF) is required for the application.
UAE LOGISTICS: Over 50 nationalities enjoy visa-free entry or visa-on-arrival access to the UAE. For nationalities requiring advance medical visa issuance, GAF Healthcare coordinates the application through the General Directorate of Residency and Foreigners Affairs (GDRFA), with support from the receiving hospital's international patient services department. Patients from GCC countries face minimal entry requirements. A Dubai Health Authority (DHA) or Department of Health (DoH Abu Dhabi) facility approval letter is provided for insurance and visa purposes.
AIRPORT AND GROUND TRANSFERS: Dedicated air-conditioned private vehicle transfers are arranged for the patient and attendant upon arrival and at discharge. For patients requiring stretcher transport or medical escort due to advanced disease or post-operative status, GAF Healthcare coordinates with licensed medical transport providers.
DEDICATED PATIENT COORDINATORS AND INTERPRETERS: Every GAF Healthcare patient is assigned a dedicated case coordinator who is available 7 days a week. Certified medical interpreters are available for Arabic, Russian, French, Swahili, Bengali, Uzbek, and other languages in both destinations. Interpreters accompany patients to all oncology consultations, surgical consent meetings, and discharge briefings.
ACCOMMODATION FOR ATTENDANTS: GAF Healthcare has negotiated rates with hospital-affiliated guesthouses and partner hotels within a 5–10 minute radius of all partner hospitals in Mumbai, Delhi, Chennai, Hyderabad, Dubai, and Abu Dhabi. Attendant accommodation packages include daily housekeeping, laundry, and Wi-Fi. For patients requiring extended stays during the neoadjuvant therapy phase, serviced apartment arrangements (1–3 months) are available at discounted rates.
CONTINUITY OF CARE DOCUMENTATION: At discharge, GAF Healthcare compiles a complete medical dossier — including operative reports, histopathology, molecular profiling results, imaging CDs, discharge summary, and oncologist contact details — formatted for easy handoff to the patient's home oncology team, ensuring uninterrupted GIST surveillance and TKI management upon return.